Advanced glycation in diabetic patients leads to cataracts

Article

The higher level of advanced glycation end products (AGE) in senile diabetic patients may correlate to a higher rate of cataract development, according to a study published in the May?June 2008 issue of the Journal of Diabetes and its Complications.

The higher level of advanced glycation end products (AGE) in senile diabetic patients may correlate to a higher rate of cataract development, according to a study published in the May–June 2008 issue of the Journal of Diabetes and its Complications.

Anjuman Gul, MBBS, MPhil of the Department of Biochemistry, Ziauddin University, Pakistan and colleagues performed a noncompetitive enzyme linked immunosorbent assay (ELISA) with a polyclonal anti-AGE antibody to study AGE immunoreactivity and investigate the link between AGE and cataract formation. Four senile study groups were assessed: non-diabetic non-cataract subjects (n=31); diabetic non-cataract subjects (n=33); diabetic cataract subjects (n=30); and non-diabetic cataract subjects (n=30). A fifth group (young non-diabetic non-cataract subjects; n=31) was also included in the evaluation.

Amongst the four senile groups, diabetic patients had significantly increased levels of fasting blood glucose, glycosylated haemoglobin and serum fructosamine when compared with non-diabetic patients, regardless of the presence (or non-presence) of cataracts. Cataract patients had significantly increased levels of serum AGEs compared with non-cataract patients; diabetic subjects also had increased serum AGE levels, but these were higher in those with cataracts than those without. Young patients had significantly lower AGE levels than any other group.

Thus the researchers concluded that senile diabetic subjects are prone to cataract development because of the distribution of AGEs in these subjects. This reinforces the theory that the advanced glycation process may have a role in cataract formation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.